Paromomycin for cryptosporidiosis in AIDS

A prospective, double-blind trial

A. Clinton White, Cynthia L. Chappell, C. Sikander Hayat, Kay T. Kimball, Timothy P. Flanigan, Richard W. Goodgame

Research output: Contribution to journalArticle

149 Citations (Scopus)

Abstract

To test the effects of paromomycin, 10 patients with AIDS and cryptosporidiosis were randomized to paromomycin or placebo in a double- blind trial. After 14 days, patients were switched to the other treatment for 14 additional days. Measures included the number and character of each stool and weekly 24-h stool specimens for weight and oocyst excretion. During the paromomycin treatment phase, oocyst excretion decreased from 314 x 106 to 109 x 106/24 h (P < .02). Oocyst excretion increased for the 4 patients initially on placebo compared to a median decrease of 128 x 106/24 h for the 6 initially treated with drug (P < .02). Stool frequency also decreased more in those treated with drug (3.6 fewer vs. 1.25 fewer/24 h, P < .05). Trends favored drug over placebo for stool weight, stool character, and Karnofsky score. Paromomycin treatment resulted in improvement in both clinical and parasitologic parameters in cryptosporidiosis in AIDS.

Original languageEnglish (US)
Pages (from-to)419-424
Number of pages6
JournalJournal of Infectious Diseases
Volume170
Issue number2
StatePublished - Aug 1994
Externally publishedYes

Fingerprint

Paromomycin
Cryptosporidiosis
Oocysts
Acquired Immunodeficiency Syndrome
Placebos
Pharmaceutical Preparations
Weights and Measures
Therapeutics

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

White, A. C., Chappell, C. L., Hayat, C. S., Kimball, K. T., Flanigan, T. P., & Goodgame, R. W. (1994). Paromomycin for cryptosporidiosis in AIDS: A prospective, double-blind trial. Journal of Infectious Diseases, 170(2), 419-424.

Paromomycin for cryptosporidiosis in AIDS : A prospective, double-blind trial. / White, A. Clinton; Chappell, Cynthia L.; Hayat, C. Sikander; Kimball, Kay T.; Flanigan, Timothy P.; Goodgame, Richard W.

In: Journal of Infectious Diseases, Vol. 170, No. 2, 08.1994, p. 419-424.

Research output: Contribution to journalArticle

White, AC, Chappell, CL, Hayat, CS, Kimball, KT, Flanigan, TP & Goodgame, RW 1994, 'Paromomycin for cryptosporidiosis in AIDS: A prospective, double-blind trial', Journal of Infectious Diseases, vol. 170, no. 2, pp. 419-424.
White AC, Chappell CL, Hayat CS, Kimball KT, Flanigan TP, Goodgame RW. Paromomycin for cryptosporidiosis in AIDS: A prospective, double-blind trial. Journal of Infectious Diseases. 1994 Aug;170(2):419-424.
White, A. Clinton ; Chappell, Cynthia L. ; Hayat, C. Sikander ; Kimball, Kay T. ; Flanigan, Timothy P. ; Goodgame, Richard W. / Paromomycin for cryptosporidiosis in AIDS : A prospective, double-blind trial. In: Journal of Infectious Diseases. 1994 ; Vol. 170, No. 2. pp. 419-424.
@article{6090f841a1524037a31b1e1b399e109b,
title = "Paromomycin for cryptosporidiosis in AIDS: A prospective, double-blind trial",
abstract = "To test the effects of paromomycin, 10 patients with AIDS and cryptosporidiosis were randomized to paromomycin or placebo in a double- blind trial. After 14 days, patients were switched to the other treatment for 14 additional days. Measures included the number and character of each stool and weekly 24-h stool specimens for weight and oocyst excretion. During the paromomycin treatment phase, oocyst excretion decreased from 314 x 106 to 109 x 106/24 h (P < .02). Oocyst excretion increased for the 4 patients initially on placebo compared to a median decrease of 128 x 106/24 h for the 6 initially treated with drug (P < .02). Stool frequency also decreased more in those treated with drug (3.6 fewer vs. 1.25 fewer/24 h, P < .05). Trends favored drug over placebo for stool weight, stool character, and Karnofsky score. Paromomycin treatment resulted in improvement in both clinical and parasitologic parameters in cryptosporidiosis in AIDS.",
author = "White, {A. Clinton} and Chappell, {Cynthia L.} and Hayat, {C. Sikander} and Kimball, {Kay T.} and Flanigan, {Timothy P.} and Goodgame, {Richard W.}",
year = "1994",
month = "8",
language = "English (US)",
volume = "170",
pages = "419--424",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Paromomycin for cryptosporidiosis in AIDS

T2 - A prospective, double-blind trial

AU - White, A. Clinton

AU - Chappell, Cynthia L.

AU - Hayat, C. Sikander

AU - Kimball, Kay T.

AU - Flanigan, Timothy P.

AU - Goodgame, Richard W.

PY - 1994/8

Y1 - 1994/8

N2 - To test the effects of paromomycin, 10 patients with AIDS and cryptosporidiosis were randomized to paromomycin or placebo in a double- blind trial. After 14 days, patients were switched to the other treatment for 14 additional days. Measures included the number and character of each stool and weekly 24-h stool specimens for weight and oocyst excretion. During the paromomycin treatment phase, oocyst excretion decreased from 314 x 106 to 109 x 106/24 h (P < .02). Oocyst excretion increased for the 4 patients initially on placebo compared to a median decrease of 128 x 106/24 h for the 6 initially treated with drug (P < .02). Stool frequency also decreased more in those treated with drug (3.6 fewer vs. 1.25 fewer/24 h, P < .05). Trends favored drug over placebo for stool weight, stool character, and Karnofsky score. Paromomycin treatment resulted in improvement in both clinical and parasitologic parameters in cryptosporidiosis in AIDS.

AB - To test the effects of paromomycin, 10 patients with AIDS and cryptosporidiosis were randomized to paromomycin or placebo in a double- blind trial. After 14 days, patients were switched to the other treatment for 14 additional days. Measures included the number and character of each stool and weekly 24-h stool specimens for weight and oocyst excretion. During the paromomycin treatment phase, oocyst excretion decreased from 314 x 106 to 109 x 106/24 h (P < .02). Oocyst excretion increased for the 4 patients initially on placebo compared to a median decrease of 128 x 106/24 h for the 6 initially treated with drug (P < .02). Stool frequency also decreased more in those treated with drug (3.6 fewer vs. 1.25 fewer/24 h, P < .05). Trends favored drug over placebo for stool weight, stool character, and Karnofsky score. Paromomycin treatment resulted in improvement in both clinical and parasitologic parameters in cryptosporidiosis in AIDS.

UR - http://www.scopus.com/inward/record.url?scp=0028238931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028238931&partnerID=8YFLogxK

M3 - Article

VL - 170

SP - 419

EP - 424

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 2

ER -